MATRIX METALLOPROTEINAZA-9 VA UNING TO‘QIMASI INHIBITORI-1 NING MIYA QON-TOMIRLARI PATOLOGIYASINING MUMKIN BO‘LGAN BASHORATCHISI SIFATIDAGI ROLI
##article.subject##:
matritsa metalloproteinaza (MMP-9), matritsa metalloproteinazaning to'qima inhibitori (TIMP-1), serebrovaskulyar kasalliklar##article.abstract##
50 yoshdan 78 yoshgacha bo'lgan serebrovaskulyar kasalliklar va insult bilan kasallangan jami 87 nafar bemor tekshirildi, o'rtacha yoshi 67,9±4,8 yil. Serebrovaskulyar kasalliklarga chalingan bemorlarda MMP-9, TIMP-1 va qon zardobida ularning nisbati ortishi tendentsiyasi aniqlandi, ularning ko'rsatkichlari serebrovaskulyar jarayonning og'irligini bashorat qiluvchi omil sifatida qaralishi mumkin.
Библиографические ссылки
Berezhanskaya S.B., Lukyanova E.A., Zhavoronkova T.E., Kaushanskaya E.Y., Sozaeva D.I. Modern concept of structural and functional organization of the blood-brain barrier and the main mechanisms of its resistance violation resistance. Pediatrics. 2017;96(1):135-141. (in Russ).
Grigorkevich O.S., Mokrov G.V., Kosova L.Y. Matrix metalloproteinases and their inhibitors // Pharmacokinetics and Pharmacodynamics. 2019; 2: 3-16. DOI: 10.24411/2587-7836-2019-10040. (in Russ).
Konstantinova E.V., Shurdumova M.H. Destruction and remodeling of extracellular matrix in the pathogenesis of acute focal cerebral ischemia pathogenesis of acute focal cerebral ischemia. Consilium Medicum. 2015; 17 (12): 50-54. (in Russ).
Markelova E.V., Zdor V.V., Romanchuk A.L., et al. Matrix metalloproteinases: their interrelation with cytokine system, diagnostic and prognostic potential // Immunology, Allergology, Infectology. - 2016;2:11-22. (in Russ).
Paltsin A.A. Matrix proteinases in stroke / Pathologic physiology and experimental therapy experimental therapy. 2017;61(3):110-115. (in Russ).
Reznik E.V., Krupnova E.S., Bilinskaya M.A., Yasnovskaya A.A., Nikitin I.G., Perekhodovi S.N. Matrix metalloproteinases, their inhibitors and inflammatory markers in patients with chronic heart failure patients with chronic heart failure. RMZ. 2023;9:12-17. (in Russ).
Teplyakov A.T., Andriyanova A.V., Pushnikova E.Yu. et al. Tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) as an independent marker of myocardial ischemic remodeling in chronic insufficiency. Siberian Medical Journal. 2014;29(2):28-34. (in Russ).
Shadrina AS, Plieva YZ, Kushlinsky DN, Morozov AA, Filipenko ML, Chang VL, Kushlinsky NE Classification, regulation of activity, genetic polymorphism of matrix metalloproteinases in norm and pathology / Almanac of Clinical Medicine. 2017;45(4):266–279. doi: 10.18786/2072-0505-2017-45-4-266-279. (in Russ).
Translated with DeepL.com (free version) Freitas-Rodríguez S, Folgueras AR, López Otín C. The role of matrix metalloproteinases in aging: Tissue remodeling and beyond. Biochim Biophys Acta, 2017; 0167-4889(17)30118-0. doi: 10.1016/j.bbamcr.2017.05.007.
Laronha, H. Structure and Function of Human Matrix Metalloproteinases / H. Laronha, J. Caldeira // Cells. 2020; 9(5):1076.
Levin M, Udi Y, Solomonov I, Sagi I. Next Generation Matrix Metalloproteinase Inhibitors – Novel Strategies Bring New Prospects. Biochim Biophys Acta, 2017;0167-4889(17)30161-1. doi: 10.1016/j.bbamcr.2017.06.009.
Van Lint, P. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation / P. Van Lint, C. Libert // J Leukoc Biol, 2007;82(6):1375-1381.
